Tuberculosis Pipeline Analysis Report 2026

Tuberculosis (TB) is a contagious airborne bacterial infection caused by Mycobacterium tuberculosis, primarily affecting the lungs but potentially impacting other organs. According to the World Health Organization, around 10.7 million people developed TB globally in 2024, reflecting a significant disease burden. Current therapies include first-line antibiotics, multidrug-resistant TB regimens, and emerging all-oral treatments. According to the tuberculosis pipeline analysis, there is growing focus on novel drug combinations, shorter regimens, and host-directed therapies. Increasing drug resistance, rising R&D investments, and advancements in diagnostics are expected to drive pipeline expansion and market growth in the coming years.

Report Coverage

The Tuberculosis Pipeline Analysis Report gives comprehensive insights into tuberculosis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for tuberculosis. The tuberculosis report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The tuberculosis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with tuberculosis treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to tuberculosis.

Tuberculosis Pipeline Outlook

Tuberculosis (TB) is an infectious disease caused by the bacterium Mycobacterium tuberculosis. It primarily affects the lungs but can spread to other organs. Transmission occurs via airborne droplets from coughs or sneezes of infected individuals, leading to latent or active infection when bacteria invade lung tissue and multiply.

Tuberculosis treatments involve standard regimens like HRZE (isoniazid, rifampin, pyrazinamide, ethambutol) for drug-sensitive TB, typically lasting 6 months. Drug-resistant cases use longer courses with bedaquiline, pretomanid, and linezolid, emphasizing adherence to prevent resistance. In November 2025, TB Alliance's Phase 2 NC-009 trial results revealed that sorfequiline (TBAJ-876), combined with pretomanid and linezolid in the SPaL regimen, outperformed standard HRZE for drug-sensitive TB, showing potential to shorten treatment duration while maintaining a comparable safety profile.

Tuberculosis Epidemiology

Tuberculosis remains a pressing global health challenge, demanding robust drug pipeline advancements. According to the World Health Organization (WHO) Global Tuberculosis Report 2025, an estimated 10.7 million people (95% uncertainty interval: 9.9-11.5 million) developed TB in 2024, equating to 131 incident cases per 100,000 population. Men comprised 54% of cases, women 35%, and children/young adolescents 11%. In India, per Ghanshyam Ahirwar et al. (2025) citing India TB Report 2024, the country bore 26% of the global burden with 2.7 million cases in 2023, achieving 89% treatment coverage and a 17.7% incidence decline to 195 per 100,000 population. Strategic drug innovations are vital for accelerating TB elimination.

Tuberculosis - Pipeline Therapeutic Assessment

This section of the report covers the analysis of tuberculosis drug candidates based on several segmentations, including:

By Phase

The pipeline assessment report covers 50+ drug analyses based on phase:

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

The tuberculosis pipeline analysis report covers 50+ drug analyses based on drug classes:

• Small Molecules
• Oligonucleotides
• Peptides

By Route of Administration

The pipeline assessment report covers 50+ drug analyses based on the route of administration:

• Oral
• Parenteral
• Others

Tuberculosis Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total tuberculosis clinical trials, commands 38%, accelerating efficacy validation. Phase III with 35%, ensuring regulatory readiness. Phase I contributes 15%, fostering novel discoveries. Phase IV adds 12%, enhancing post-approval optimization. Overall, this phase-wise distribution reflects a well-balanced and advancing pipeline, indicating sustained innovation and a strong trajectory toward improved tuberculosis treatment outcomes.

Tuberculosis Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the tuberculosis pipeline analysis include small molecules, oligonucleotides, and peptides. The tuberculosis report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for tuberculosis. Novel drug classes for tuberculosis are advancing to address drug-resistant strains and improve treatment outcomes. For instance, in April 2025, the World Health Organization introduced a 6-month all-oral BDLLfxC regimen for multidrug-resistant tuberculosis. Moreover, diarylquinolines, nitroimidazoles, and oxazolidinones such as bedaquiline, pretomanid, and linezolid are under evaluation to enhance efficacy and reduce treatment duration.

Tuberculosis Clinical Trials - Key Players

The report for the tuberculosis pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed tuberculosis therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in tuberculosis clinical trials:

• BioNTech SE
• Quratis Inc.
• Thirty Respiratory Limited
• WestVac Biopharma Co., Ltd.
• Chengdu CoenBiotech Co., Ltd.
• Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
• CanSino Biologics Inc.
• Biofabri, S.L
• BioVersys AG
• Otsuka Pharmaceutical Development & Commercialization, Inc.
• Bharat Biotech International Limited
• Shanghai Jiatan Pharmatech Co., Ltd.

Tuberculosis - Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for tuberculosis. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of tuberculosis drug candidates.

Drug: JDB0131

JDB0131 Benzenesulfonate is being investigated by WestVac Biopharma Co., Ltd. in a Phase 2b clinical study for drug-resistant tuberculosis. This study is evaluating the efficacy, safety, and pharmacokinetics of oral JDB0131 tablets at varying doses compared with delamanid-based combination regimens. JDB0131 is a novel third-generation nitroimidazole that inhibits mycobacterial cell wall synthesis and generates reactive nitrogen species, enhancing bactericidal activity. The trial is enrolling patients and is expected to reach primary completion by February 2026, with overall study completion anticipated by September 2026.

Drug: BNT164

BNT164a1 and BNT164b1 are investigational mRNA-based tuberculosis vaccines sponsored by BioNTech SE, currently being evaluated in a Phase Ib/IIa study that is examining safety, tolerability, and immunogenicity in BCG-vaccinated, HIV-negative individuals. These vaccines are encoding eight Mycobacterium tuberculosis antigens and are being administered via intramuscular injection in a three-dose schedule. The study is assessing dose escalation and immune response generation, including T-cell activation and antibody production. Researchers identify optimal dosing while monitoring reactogenicity. The primary completion was achieved in March 2026, with overall study completion expected by January 2027.

Biological: QTP101

QTP101 (ID93+GLA-SE) is a recombinant subunit tuberculosis vaccine being developed by Quratis Inc., designed as a multi-antigen protein fusion combining four Mycobacterium tuberculosis antigens with a GLA-SE adjuvant that activates Toll-like receptor 4 to enhance Th1 immune responses. The Phase 1 trial is evaluating safety and immunogenicity in BCG-vaccinated adults aged 55-74 years. The study is administering three intramuscular injections on Days 0, 28, and 56, while monitoring antibody and cytokine responses. The trial is being completed by December 2026, supporting future TB prevention strategies in aging populations.

Key Questions Answered in the Tuberculosis Pipeline Insight Report

• Which companies/institutions are leading tuberculosis drug development?
• Which company is leading the tuberculosis pipeline development activities?
• What is the current tuberculosis commercial assessment?
• What are the opportunities and challenges present in the tuberculosis pipeline landscape?
• What is the efficacy and safety profile of tuberculosis pipeline drugs?
• Which company is conducting major trials for tuberculosis drugs?
• Which companies/institutions are involved in tuberculosis collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in tuberculosis?

Reasons To Buy This Report

The Tuberculosis Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for tuberculosis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into tuberculosis collaborations, regulatory environments, and potential growth opportunities.